ReviewCurrent cardiology reports2010
The omega-3 index: clinical utility for therapeutic intervention.
Review in Current cardiology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Omega-3 fatty acid supplementation for distal symmetrical peripheral neuropathy in adults with diabetes mellitus.The Cochrane database of systematic reviews · 2025Pooled it
- Twelve-Week Daily Consumption ofNutrients · 2020Trial
- Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease.Journal of the American Heart Association · 2020Trial
- Effects of exergame training combined with omega-3 fatty acids on the elderly brain: a randomized double-blind placebo-controlled trial.BMC geriatrics · 2019Trial
- Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial.Lipids in health and disease · 2016Trial
- Preemptive enteral nutrition enriched with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in severe multiple trauma: a prospective, randomized, double-blind study.Intensive care medicine · 2015Trial
- Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial.Molecular and cellular biochemistry · 2014Trial
- Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Trial
- Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients.HIV medicine · 2013Trial
- Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance.Diabetes · 2013Trial
- Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial.Lipids in health and disease · 2012Trial
- Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers.Journal of lipid research · 2012Trial
- Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements.Journal of clinical lipidologyTrial
- Article
- The Erythrocyte Fatty Acid Profile in Multiple Sclerosis Is Linked to the Disease Course, Lipid Peroxidation, and Dietary Influence.Nutrients · 2025Article
- A closer look at the role of nutrition in children and adults with ADHD and neurodivergence.Frontiers in nutrition · 2025Article
- Article
- Review
- Innovative Bioactive Products with Medicinal Value from Microalgae and Their Overall Process Optimization through the Implementation of Life Cycle Analysis-An Overview.Marine drugs · 2024Review
- Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8% or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.